Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) EBITDA Margin (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed EBITDA Margin for 8 consecutive years, with 218.91% as the latest value for Q1 2026.

  • For Q1 2026, EBITDA Margin rose 7138.0% year-over-year to 218.91%; the TTM value through Mar 2026 reached 619.99%, down 21384.0%, while the annual FY2025 figure was 785.66%, 30812.0% down from the prior year.
  • EBITDA Margin hit 218.91% in Q1 2026 for Kymera Therapeutics, up from 3020.28% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 26.04% in Q4 2023 and bottomed at 3020.28% in Q4 2025.
  • Average EBITDA Margin over 5 years is 797.2%, with a median of 412.18% recorded in 2023.
  • On a YoY basis, EBITDA Margin climbed as much as 19364bps in 2025 and fell as far as -201720bps in 2025.
  • Kymera Therapeutics' EBITDA Margin stood at 210.06% in 2022, then soared by 88bps to 26.04% in 2023, then tumbled by -3752bps to 1003.08% in 2024, then plummeted by -201bps to 3020.28% in 2025, then skyrocketed by 93bps to 218.91% in 2026.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 218.91%, 3020.28%, and 2928.84% for Q1 2026, Q4 2025, and Q3 2025 respectively.